Added to YB: 2026-09-25
Pitch date: 2026-09-23
NKTR [bullish]
Nektar Therapeutics
-36.86%
current return
Author Info
Healthcare Investing Long / Short ideas. Sign up for the newsletter.
Company Info
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally.
Market Cap
$1.4B
Pitch Price
$58.03
Price Target
120.00 (+228%)
Dividend
N/A
EV/EBITDA
-7.43
P/E
-6.53
EV/Sales
16.36
Sector
Biotechnology
Category
special_situation
The Weekly #2 - Nektar Therapeutics
NKTR (added to position): Added shares ahead of the expected verdict and owns October $80 calls. The trial assessment is that liability is trending Nektar, with a predicted $531M award; from a $62 spot, the appeal- and timing-discounted verdict scenario is ~$75, while 9% prejudgment interest could add another $12-$15 per share. The unresolved risks are the jury’s decision, appeal and collection timing.
Read full article (2 min)